Related Experiment Video
Updated: Jul 2, 2026
11:34
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
Injecting drug users' understanding of hepatitis C
Susannah O'Brien1, Carolyn Day, Emma Black
1National Drug and Alcohol Research Centre, University of New South Wales, NSW 2052, Australia. s.obrien@unsw.edu.au
Addictive Behaviors
|September 3, 2008
Summary
Many people who inject drugs (IDUs) have significant gaps in their understanding of Hepatitis C virus (HCV). Improved education is needed to address misconceptions about HCV transmission, symptoms, and treatment.
Area of Science:
- Hepatology
- Infectious Diseases
- Public Health
Background:
- Hepatitis C virus (HCV) infection is a significant global health concern, particularly among people who inject drugs (IDUs).
- Understanding of HCV, including transmission, symptoms, and treatment, is crucial for effective prevention and management strategies within this population.
Purpose of the Study:
- To assess the knowledge and understanding of HCV among IDUs in New South Wales, Australia.
- To identify specific gaps in knowledge regarding HCV transmission, clinical markers, symptoms, and treatment.
Main Methods:
- A cross-sectional survey was conducted with 149 IDUs recruited from various urban, suburban, and regional settings.
- Interviews were used to gather data on participants' understanding of HCV and related testing.
Main Results:
- 74% of participants reported recent HCV testing, but many showed confusion regarding test results.
- Significant knowledge gaps were identified: 19% believed they couldn't infect others if positive, 48% misunderstood transmission risks (e.g., sharing own needles), and 42% were misinformed about antibody protection.
Conclusions:
- Substantial deficiencies in HCV knowledge exist among IDUs, impacting their understanding of risks and protective measures.
- Further development and research into targeted educational strategies are essential to improve HCV literacy in this vulnerable population.
Related Concept Videos
01:25Hepatitis
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
01:28Viral Hepatitis I: Introduction
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
01:16Hepatic Drug Excretion: Influencing Factors
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:17Hepatic Drug Excretion: Enterohepatic Cycling
Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...